A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma
BACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.
861-865
Crawley, C.R.
5425cd35-b464-47d6-a7ea-cf22736d5d61
Foran, J.M.
4b469095-77d2-4c02-92ec-3d3751d4cbf0
Gupta, R. K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Rohatiner, A.Z.
6555b742-d414-4fcb-908f-f43b6de8b71a
Summers, K.
05646b22-8f86-44ef-ba11-c89d94278dd9
Matthews, J.
4c708491-7509-44d6-9375-2b7313a36f3e
Micallef, I.N.
f37b18a5-a105-48c0-a644-59bc1e308370
Radford, J.A.
77dd6342-413d-47e4-8c72-1b7829efba99
Johnson, S.A.
b3b18ab7-3e5a-416b-8306-bf27df6d6ff6
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Sweetenham, J.W.
4ea41ea4-f6aa-43c2-bb4c-804832d980e5
Lister, T. A.
0de6a9a4-2fe0-41b0-8226-a10d28d31f4c
July 2000
Crawley, C.R.
5425cd35-b464-47d6-a7ea-cf22736d5d61
Foran, J.M.
4b469095-77d2-4c02-92ec-3d3751d4cbf0
Gupta, R. K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Rohatiner, A.Z.
6555b742-d414-4fcb-908f-f43b6de8b71a
Summers, K.
05646b22-8f86-44ef-ba11-c89d94278dd9
Matthews, J.
4c708491-7509-44d6-9375-2b7313a36f3e
Micallef, I.N.
f37b18a5-a105-48c0-a644-59bc1e308370
Radford, J.A.
77dd6342-413d-47e4-8c72-1b7829efba99
Johnson, S.A.
b3b18ab7-3e5a-416b-8306-bf27df6d6ff6
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Sweetenham, J.W.
4ea41ea4-f6aa-43c2-bb4c-804832d980e5
Lister, T. A.
0de6a9a4-2fe0-41b0-8226-a10d28d31f4c
Crawley, C.R., Foran, J.M., Gupta, R. K., Rohatiner, A.Z., Summers, K., Matthews, J., Micallef, I.N., Radford, J.A., Johnson, S.A., Johnson, Peter W.M., Sweetenham, J.W. and Lister, T. A.
(2000)
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Annals of Oncology, 11 (7), .
Abstract
BACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.
This record has no associated files available for download.
More information
Published date: July 2000
Identifiers
Local EPrints ID: 157839
URI: http://eprints.soton.ac.uk/id/eprint/157839
ISSN: 1569-8041
PURE UUID: ab43fb8d-9603-4024-9cb7-328c0a947da9
Catalogue record
Date deposited: 16 Jun 2010 14:02
Last modified: 23 Jul 2022 01:43
Export record
Contributors
Author:
C.R. Crawley
Author:
J.M. Foran
Author:
R. K. Gupta
Author:
A.Z. Rohatiner
Author:
K. Summers
Author:
J. Matthews
Author:
I.N. Micallef
Author:
J.A. Radford
Author:
S.A. Johnson
Author:
J.W. Sweetenham
Author:
T. A. Lister
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
